Z-BeEAM (Ibritumomab tiuxetan, Bendamustine, Etoposide, Cytarabine, Melphalan) before autologous stem cell transplantation is safe and efficient for refractory large B-cell lymphoma

被引：3
作者：
Tardy M.P. [1 ]
Gastaud L. [1 ]
Ojeda-Uribe M. [2 ]
Boscagli A. [1 ]
Caruso S. [3 ]
Skaf R. [4 ]
Gutnecht J. [5 ]
Thyss A. [1 ]
Peyrade F. [1 ]
机构：
[1] Antoine-Lacassagne Center, Department of Oncology, Nice
[2] Mulhouse Hospital, Department of Hematology, Mulhouse
[3] La Dracenie Hospital Center, Draguignan
[4] Saint-Georges Clinic, Department of Oncology, Nice
[5] Frejus-Saint Raphael Hospital, Department of Oncology, Frejus
来源：
Experimental Hematology & Oncology | / 4卷 / 1期
关键词：
Aggressive Non-Hodgkin lymphoma; Autologous stem cell transplantation; Conditionning regimen; Large B cell lymphoma; Z-BeEAM;
D O I：
10.1186/s40164-015-0013-2
中图分类号：
学科分类号：
摘要：
Background: Refractory or relapsed large B-cells lymphoma are usually treated with a high dose chemotherapy regimen followed by an autolougous stem cells transplantation. BEAM (carmustine, etoposide, cytarabine, melphalan) or more recently Z-BEAM (ibritumomab tiuxetan and BEAM) are commonly used regimens, but recently carmustine availability became difficult. The purpose of this study was to evaluate the feasibility and the safety of replacing carmustine by bendamustine in a new Z-BeEAM regimen (ibritumomab tiuxetan, bendamustine, etoposide, cytarabine, melphalan) prior to autologous stem cell transplantation. Findings: This study was a retrospective analyze of six patients, with a median age of 60, treated by Z-BeEAM before autologous stem cell transplantation. We did not put in evidence any additional toxicities compared to conventional induction chemotherapy. The main toxicities were mucositis (3 grade III among 6 patients), gastrointestinal (2 grade III vomiting and 2 grade III diarrhea) and neutropenia (6 grade IV). Engraftment was successfully achieved for all patients. At the time of analysis of this study all patients were alive and in complete response based on the PET-CT evaluation. Conclusions: BeEAM plus ibritumomab tiuxetan combined regimen before autologous stem cell transplantation is feasible and safe in aggressive relapsing large B-cell lymphoma. © 2015 Tardy et al.
引用
收藏
相关论文
共 13 条
  • [1] Gisselbrecht C., Glass B., Mounier N., Singh Gill D., Linch D.C., Trneny M., Et al., Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era, J. Clin. Oncol., 28, pp. 4184-4190, (2010)
  • [2] Philip T., Guglielmi C., Hagenbeek A., Somers R., Lelie H., Bron D., Et al., Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma, N. Engl. J. Med., 333, pp. 1540-1545, (1995)
  • [3] Mounier N., Gisselbrecht C., Conditioning regimens before transplantation in patients with aggressive non-Hodgkin's lymphoma, Ann. Oncol., 9, pp. S15-21, (1998)
  • [4] Fruchart C., Tilly H., Morschhauser F., Ghesquieres H., Bouteloup M., Ferme C., Et al., Upfront consolidation combining yttrium-90 ibritumomab tiuxetan and high-dose therapy with stem cell transplantation in poor-risk patients with diffuse large B cell lymphoma, Biol. Blood Marrow Transplant, 20, pp. 1905-1911, (2014)
  • [5] Shimoni A., Avivi I., Rowe J.M., Yeshurun M., Levi I., Or R., Et al., A randomized study comparing yttrium-90 ibritumomab tiuxetan (Zevalin) and high-dose BEAM chemotherapy versus BEAM alone as the conditioning regimen before autologous stem cell transplantation in patients with aggressive lymphoma, Cancer, 118, pp. 4706-4714, (2012)
  • [6] Visani G., Malerba L., Stefani P.M., Capria S., Galieni P., Gaudio F., Et al., BeEAM (bendamustine, etoposide, cytarabine, melphalan) before autologous stem cell transplantation is safe and effective for resistant/relapsed lymphoma patients, Blood, 118, pp. 3419-3425, (2011)
  • [7] Cheson B.D., Fisher R.I., Barrington S.F., Cavalli F., Schwartz L.H., Zucca E., Et al., Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: the Lugano Classification, J. Clin. Oncol., 32, pp. 3059-3067, (2014)
  • [8] Fernandez H.F., Escalon M.P., Pereira D., Lazarus H.M., Autotransplant conditioning regimens for aggressive lymphoma: are we on the right road?, Bone Marrow Transplant., 40, pp. 505-513, (2007)
  • [9] Mills W., Chopra R., McMillan A., Pearce R., Linch D.C., Goldstone A.H., BEAM chemotherapy and autologous bone marrow transplantation for patients with relapsed or refractory non-Hodgkin's lymphoma, J. Clin. Oncol., 13, pp. 588-595, (1995)
  • [10] Martin N., Borchiellini D., Coso D., Gastaud L., Boscagli A., Saudes L., Et al., High-dose chemotherapy with carmustine, etoposide, cytarabine and melphalan followed by autologous stem cell transplant is an effective treatment for elderly patients with poor-prognosis lymphoma, Leuk. Lymphoma, pp. 1-9, (2015)
12